AI Insight
This study identifies cholesterol metabolism as a critical vulnerability in glioblastoma, demonstrating that combining two FDA-approved drugs (clemastine and bexarotene) synergistically kills glioblastoma cells by disrupting cholesterol processing. The treatment triggers cellular stress responses leading to cancer cell death, reduces tumor growth in mouse models, and appears to enhance immune system activation against tumors. Direct injection into the brain proved more effective than systemic delivery, requiring four times lower doses while significantly extending survival in preclinical models.
Why it matters
This research offers a potential new treatment strategy for glioblastoma, one of the most deadly and treatment-resistant brain cancers, using drugs already approved for other conditions. The approach may be particularly valuable because it appears to work synergistically with the immune system, potentially enabling combination with immunotherapies.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Glioblastoma (GBM) remains the most lethal primary brain cancer due to its remarkable metabolic plasticity and therapeutic resistance. Here, we identify cholesterol dependency as a therapeutically exploitable vulnerability in GBM using two FDA approved drugs: the H1 histamine antagonist clemastine and the retinoid X receptor agonist bexarotene. Combined treatment induces potent synergistic anti tumor activity across patient-derived glioma models, suppressing proliferation, stemness, and survival at sub IC50 concentrations. Mechanistically, this therapy disrupts cholesterol biosynthesis, transport, and homeostasis, triggering endoplasmic reticulum stress and activation of the unfolded protein response, ultimately leading to autophagy and apoptotic cell death. Orthotopic patient derived glioma models recapitulate these mechanisms in vivo, where local intracranial administration significantly reduces tumor progression and prolongs survival using fourfold lower doses than systemic intraperitoneal delivery. Single cell RNA sequencing revealed activation of regeneration and plasticity programs, accompanied by immune microenvironment remodeling and enhanced inflammatory signaling. Importantly, syngeneic models preserved immune cell composition, supporting future integration with immunotherapeutic strategies. Together, these findings establish cholesterol dysregulation induced metabolic collapse as a promising therapeutic approach for GBM.